What is Imperative Care?
Imperative Care operates at the intersection of advanced medical engineering and patient-centric care. The company specializes in the development and commercialization of connected innovations specifically engineered to improve outcomes for patients suffering from stroke and ischemic vascular diseases. By integrating digital health platforms with sophisticated robotics, Imperative Care is effectively bridging the gap between complex clinical interventions and accessible patient recovery. Their market position is defined by a commitment to enhancing the entire patient journey, from initial diagnosis to long-term vascular health management, positioning them as a key innovator in the high-growth medtech landscape.
How much funding has Imperative Care raised?
Imperative Care has raised a total of $445M across 3 funding rounds:
Series C
$85M
Series D
$260M
Debt
$100M
Series C (2019): $85M with participation from Ascension Ventures, Delos Capital, Incept LLC, 3H Health Investment, Ally Bridge Group, Rock Springs Capital, and Bain Capital
Series D (2021): $260M led by D1 Capital Partners, Innovatus Capital Partners, Ally Bridge Group, HealthCor Investments, and Bain Capital Life Sciences
Debt (2026): $100M supported by Elevage Medical Technologies, Catalio Capital Management, Perceptive Advisors, Ally Bridge Group, Brown Advisory, Bain Capital, and Longaeva Books
Key Investors in Imperative Care
Ally Bridge Group
A global healthcare investment management firm specializing in high-impact life science innovation, managing over $6 billion in transactions since 2013.
Bain Capital
A leading global private investment firm with approximately $185 billion in assets under management, known for its deep sector expertise in healthcare and special situations.
Perceptive Advisors
An investment firm managing around $7 billion in assets, focused exclusively on funding innovative healthcare and life sciences technologies.
What's next for Imperative Care?
With the recent influx of $100M, Imperative Care is well-positioned to accelerate its research and development pipeline and expand its commercial footprint. The strategic focus will likely shift toward deepening its integration of robotics and digital health tools, which are essential for scaling treatment effectiveness across diverse clinical environments. As the company moves beyond its earlier growth phases, this capital will be instrumental in navigating the complexities of global healthcare markets, ensuring that their interventional technologies reach a broader patient demographic while maintaining the high standards of clinical efficacy that have defined their growth to date.
See full Imperative Care company page
